Member Info for Flippineck

The RNS of 29 August confirmed significant changes to the Convertible Bond and repayments. We raised additional funding at that time and further fundraising since. Wording in that RNS seemed to indicate we expect significant developments by mid 2026.

Despite this recent volatility I believe the company, with its groundbreaking science platform, is worth significantly more than our circa 300m market cap. I think others do too. The first half of next year will be very exciting in my opinion.

GLA

The RNS of 8th December made it very clear that today was about release of data for Phase 1b Trial in SGC cohort. That is exactly what we have been given.

Very happy with the direction of travel here and pleased to read the views of posters who I greatly respect. Looking forward to the presentation at 10am.

It is odd to hear a prolific poster won’t be bothering to watch the presentation but each to their own.

GLA

Unicorno has very few posts to his name - I think they are very balanced and well worth reading.

GLA

It was posted 7 December by WelshFalcon.

Yes, it’s crazy - big Pharma are going to completely miss out on the news!

Wyn, I would have happily recommended your post until I read your final paragraph in which you made such a sweeping condemnation of your fellow investors.

It is clear to me we have many investors who have great interest in the science and we have many who have invested because they, or their loved ones, have been affected by cancer and they wish to support this company. Why would it be a selfish thing to invest in a company trying to make a difference?

You, on the other hand, regularly preach to us that it’s all about the money. Stop being such a hypocrite.

The US stock market is closed today and has a shortened trading period tomorrow due to Thanksgiving. It re-opens on Monday.

Next week therefore is a reasonable guess for the RNS we await, providing all the data we await is ready. As others have said it needs to be comprehensive and accurate and it will come when it’s ready.

I’m getting fed up waiting for Santa. Surprised he hasn’t turned up yet. It’s totally unacceptable.

I agree Bella. Thursday 4th December would fit in with the seminar on that date in London which I understand Avacta is attending alongside such as Novartis, Roche, AstraZeneca and Johnson and Johnson. Courtesy of @tom the bomb.

@avacta apparently billed as an “ unmissable event highlight”!

More like 25% gain but I take your point. Decent rise.

Certainly over a period of many years and thousands of posts I honestly cannot recollect him giving any enthusiasm, support or congratulations to management or our scientists for their achievements.

All this whilst regularly telling us of the profits he has supposedly made from his trading in Avacta. It’s all a bit sad in my view.

Under the previous regime Avacta lost a great deal of trust and credibility. Once lost, trust is hard to regain. The “naysayers” had a field day.

CC has totally transformed this company and Its prospects. The science continues to be astonishing and groundbreaking. Brick by brick the wall of trust is being rebuilt. In my view the share price will react and accelerate upwards as word gets out to a much wider audience.

“ Why do presentations?”

I presume it is to let shareholders, potential investors and interested parties know what is going on. Would you prefer we were kept in the dark? Maybe it’s just to satisfy Wyn who never has any idea what’s happening!

When you buy in an open offer you are directly putting money into the company. When you buy shares in the open market you help the company by maintaining or improving the share price, hence the company’s market cap and ability to raise capital, if needed, at a better share price.

Shareholders therefore have been able to assist the company in these ways.

You only need one if your investment horizon is in milliseconds!

Most traders haven’t a clue.

Many moons ago our scientists stated they “ wanted to become masters of FAP”.

I think they have achieved it.

If the peptide drug conjugate is cleaved by FAP then I think release of the payload happens in just the same way, regardless of it being one or two payloads inside. I wouldn’t think more FAP would be used up. Not a scientist by the way!!

Avacta have clearly stated they are now able to” to release two drugs from one precision molecule”.

None of us know what’s round the corner but your reasoning sounds logical to me. Good luck.

5pm